[co-author: Vicky Vlontzou]
The Belgian Federal Agency for Medicines and Health Products (AFMPS) has announced that it has abolished measures introducing quotas for the supply of paracetamol-based medicinal products. The measures had previously been imposed on pharmaceutical companies and wholesaler-distributors to prevent shortages of these medicinal products during the COVID-19 pandemic.
On 14 April 2020, the Belgian Federal Agency for Medicines and Health Products (AFMPS), made an announcement that measures concerning the supply of paracetamol in medicinal products would be relaxed. Since 19 March 2020, pharmaceutical companies, wholesalers, and distributors have been obliged to comply with quotas that limited the supply of paracetamol-based medicinal products to pharmacies.
In light of the fact that sales of paracetamol-based medicinal products appear to have returned to normal, restrictions regarding the supply of paracetamol-based medicinal products have now been abolished. The AFMPS, however, continues to closely monitor available stocks.
The announcement states, however, that quotas shall remain for paracetamol administered intravenously.
Moreover, the limitation of supply of one box of paracetamol per person, which was introduced on 19 March 2020, shall still remain in force.
It is anticipated that remaining measures will gradually be relaxed as the supply of paracetamol medicinal products returns to normal.
[View source.]
